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Accurate determination of human epidermal growth factor receptor-2 (HER2) status is essential for
optimal selection of breast cancer patients for gene targeted therapy. The analytical performance
of microarray analysis using TargetPrint for assessment of HER2 status was evaluated in 138 breast
tumours, including 41 fresh and 97 formalin-ﬁxed parafﬁn embedded (FFPE) specimens. Reﬂex testing
using immunohistochemistry/in situ hybridization (IHC/ISH) in four discordant cases conﬁrmed the
TargetPrint results, achieving 100% agreement regardless of whether fresh tissue or FFPE specimens
were used. One equivocal IHC/ISH case was classiﬁed as HER2-positive based on the microarray result.
The proven clinical utility in resolving equivocal and borderline cases justiﬁes modiﬁcation of the
testing algorithm under these circumstances, to obtain a deﬁnitive positive or negative test result
with the use of microarrays. Determination of HER2 status across three assay platforms facilitated
improved quality assurance and led to a higher level of conﬁdence on which to base treatment
decisions.
© 2014 Elsevier Ltd. All rights reserved.Introduction
Overexpression of the human epidermal growth factor receptor-
2 (HER2) occurs in 15e20% of all invasive breast cancers. Quanti-
ﬁcation of HER2 status plays an integral role in breast cancer
prognostication and prediction of the response to HER2-targeted
therapies, shown to result in a 30e50% improvement in disease-
free and overall survival when combined with chemotherapy [1].
Assessment of HER2 status is therefore recommended in all pa-
tients with invasive breast cancer using immunohistochemistry
(IHC) [2]. However, up to 20% of test results may be inaccurate,
especially where testing is not centralised.þ27 82 8799108(mobile);In an attempt to reduce variability in HER2 testing, the American
Society of Clinical Oncology/College of American Pathologists
(ASCO/CAP) recommended that laboratories should demonstrate
high concordance when comparing their results of HER2 testing
with other validated HER2 tests [2]. Adoption of international
external quality control measures improved the reliability and
standardization of IHC HER2 testing. Fluorescence in-situ hybrid-
isation (FISH) should be performed routinely in equivocal IHC
2 þ cases, but small tumour size may be a limiting factor. Complete
depletion of the invasive component of the tumourmay occur and a
high degree of discordance has been reported between different
laboratories using FISH [3]. Interpretation of IHC/FISH results may
be particularly challenging in cases with tumour heterogeneity or
chromosome 17 polysomy. According to the ASCO/CAP revised
criteria reﬂex testing should be performed in equivocal cases using
an alternative assay. HER2 equivocal results and variability in
Fig. 1. Selection of 41 fresh and 97 FFPE tumour specimens for comparative analysis of
HER2 status between microarray analysis (TargetPrint) and standard IHC/FISH.
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was identiﬁed as a gap in the literature as the decision to treat is by
nature dichotomous (yes or no). The need for obtaining optimal test
results warrants the development of novel methods that may be
applied in conjunction with standard pathology to provide a
deﬁnitive guidance in HER2 targeted therapy.
While determination of HER2 status based on mRNA expression
levels has already been introduced into clinical practice, the ASCO/
CAP Update Committee is of the opinion that there is insufﬁcient
evidence to support the use of genomic tests for this purpose [2].
Reverse transcriptase polymerase chain reaction (RT-PCR) is indeed
considered unsuitable for determination of HER2 status [4]. This
limitation was highlighted by concerns over the value of assessing
HER2 status as part of the RT-PCR method used for the 21-gene
Oncotype DX assay, which led to inappropriate HER2 targeted
treatment in some patients [5,6]. Determination of HER2 status
using multi-gene proﬁling tests is therefore not recommended due
to potential clinical implications of inaccurate results and the
impact on cost-effectiveness [6,7]. However, whether this restric-
tion also applies to microarray-based multi-gene assays remains
unclear, especially when formalin ﬁxed parafﬁn embedded (FFPE)
tumour tissue is used. Sapino et al. [8] successfully transferred
microarray analysis using the 70-gene MammaPrint test from the
initial use of fresh tumour to the more convenient use of FFPE tis-
sue; however, a direct comparison between protein expression
(IHC) and microarray-based mRNA expression (TargetPrint) for
assessment of HER2 status using FFPE specimens has not been re-
ported previously in relation to reﬂex testing in discordant cases.
HER2 status is reported as a separate read-out (TargetPrint)
from the versatile MammaPrint microarray that enables the iden-
tiﬁcation of a subgroup of low-risk patients with HER2-positive
breast cancer [9]. In patients classiﬁed as low-risk according to
the 70-gene MammaPrint proﬁle, chemotherapy can be safely
avoided without compromising long-term clinical outcome [10].
MammaPrint has been available in South Africa since 2007, and in
2009 local referral guidelines have been adopted to improve cost-
effectiveness [11]. These guidelines referred to as the MammaP-
rint prescreen algorithm (MPA), exclude hormone receptor nega-
tive and HER2 positive patients for reimbursement by medical aid
funders. This resulted in a highly selected study population of HER2
negative cases, as well as IHC/ISH equivocal and borderline HER2-
positive cases that could be further assessed in relation to the
clinical dilemma presented under these circumstances.
The aim of the study was to determine the level of agreement
between HER2 status based on TargetPrint compared to standard
IHC/FISH performed at various local laboratories in South Africa. To
our knowledge, the clinical utility of TargetPrint using FFPE tumour
specimens for the majority of samples tested has not previously
been investigated at the interface between the laboratory and the
clinic. Analytical validation of TargetPrint in the South African
population is important due to the signiﬁcant impact of HER2
status on treatment decision-making. Quality assurance may also
be improved as a result of this study by obtaining a second opinion
of HER2 status based on objective microarray analysis.
Subjects and methods
A central genomics database was established to collect data
from South African breast cancer patients using an ethically
approved protocol. MammaPrint became commercially available in
South Africa after approval of the test by the Food and Drug
Administration (FDA) in 2007. TargetPrint was added as a separate
read-out from the MammaPrint microarray platform from 2009,
providing quantitative estrogen receptor (ER), progesterone re-
ceptor (PR) and HER2 status.Study population
From a total of 157 early-stage breast cancer tumours success-
fully analysed using the 70-gene MammaPrint microarray proﬁler,
19 cases were excluded from this study as TargetPrint was not
performed prior to 2009. Of the remaining 138 tumours, RNA was
extracted for microarray analysis from 41 fresh tumours and 97
FFPE tissue biopsies. The TargetPrint mRNA expression levels were
compared with routinely performed IHC and in situ hybridisation
(ISH) assessments of HER2 status. As outlined in Fig. 1, HER2 as-
sessments based on protein expression (IHC), DNA ampliﬁcation
(FISH) and mRNA expression (TargetPrint) were performed in a
total of 127 samples. A FISH result was not available for 11 of the
138 specimens subjected to TargetPrint.Analysis of HER2 status using immunohistochemistry (IHC)
Assessment of HER2 status by protein expression using IHC was
performed during routine analysis according to local laboratory
procedures. Resected surgical specimens or needle core biopsies
were ﬁxed in 10% neutral buffered formalin for 6e48 h as speciﬁed
in the 2013 ASCO/CAP guidelines for HER2 testing. Tissue blocks
were processed according to analytically validated protocols and
3 mm parafﬁn embedded tissue sections were mounted on Histo-
Bond® (Marienﬁeld GmbH& Co. KG, Lauda-K€onigshofen, Germany)
positively charged slides. Slides were baked at 60 C for 30 min in
an incubator. Dewaxing and staining of slides were performed on
the Leica Bond III™ automated IHC/ISH instrument (Leica Bio-
systems Pty Ltd, Melbourne, Australia) using the Bond Polymer
Reﬁne Detection kit (Cat.DS9800) with diaminobenzidine (DAB)
chromogen. The primary antibody, Novocastra™ HER2 (Leica Bio-
systems, Newcastle, UK) clone 10A7 (Cat. NCL-L-CBE) targeting the
external domain of the cell membrane, was diluted 1:50 using
Bond™ Primary antibody diluent (Cat.AR9352). Pre-treatment was
performed at a pH of 6 for 10 min at room temperature using the
Bond™ Epitope Retrieval 1 solution (Cat. AR9961). The primary
antibody was incubated for 20 min at room temperature. Positive
control sections containing known positive 2þ and 3 þ tumour
sections were added to each slide for quality control purposes. Non-
speciﬁc staining for each detection kit was performed omitting the
primary antibody. The manufacturer's diaminobenzidine (DAB)
detection kit was used that includes the biotin-free polymerase
Table 1
Clinical characteristics and HER2 status presented in relation to the 70-gene
MammaPrintmicroarray proﬁle performed in 138 tumours of breast cancer patients.
70-gene proﬁle
Total Lowrisk (%) High-risk (%)
Total 138 84 (60.9) 54 (39.1)
Specimen
Fresh 41 (29.7) 25 (61) 16 (39)
FFPE 97 (70.3) 59 (60.8) 38 (39.2)
Age (years), mean 53.1 54.8 50.6
<36 6 (4.3) 2 (33.3) 4 (66.7)
36e45 29 (21) 14 (48.3) 15 (51.7)
46e55 49 (35.5) 32 (65.3) 17 (34.7)
>55 54 (39.1) 36 (66.7) 18 (33.3)
Tumour Type
Ductal 114 (82.6) 66 (57.9) 48 (42.1)
Lobular 21 (15.2) 15 (71.4) 6 (28.6)
Mucinous 3 (2.2) 3 (100) 0 (0)
Ductal Ca Grade
1 31 (27.2) 21 (67.7) 10 (32.3)
2 62 (54.4) 36 (58.1) 26 (41.9)
3 20 (17.5) 8 (40) 12 (60)
N/Aa 1 (0.9) 1 (100) 0
a N/A, not available.
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detection of tissue-bond mouse and rabbit IgG and some mouse
IgM primary antibodies, with DAB as the localisation reagents.
Positive c-erb B2 staining of membranes were evaluated and scored
using the 2013 ASCO/CAP guidelines recommendations for HER2
testing in breast cancer. External quality control and assessment of
IHC protocols were validated by submission of in-house and
UKNEQAS stained slides to UKNEQAS (United Kingdom-National
External Quality Assessment scheme) for evaluation of IHC pro-
tocols in the reference laboratory.
Analysis of HER2 status using in situ hybridisation
FFPE specimens were investigated for HER2 gene ampliﬁcation
using the Vysis PathVysion HER-2 DNA probe kit [12]. Locus Speciﬁc
HER2 and chromosome 17 control FISH probes were used to eval-
uate the distribution ratio of HER2 to control chromosome 17
centromeric probe signals (HER2/CEP17). FISH was generally not
performed in IHC-negative (0/1þ) cases, except when discrep-
ancies were reported. In cases where IHC 2þ or 3þ scoring of HER2
was reported, FISH was performed on request of the treating
oncologist. Eleven of the IHC 2 þ tumours had no further FISH
testing due to the above-mentioned limitations and treatment or
cost considerations. All IHC 3þ tumours were also tested by FISH as
local medical insurers only fund anti-HER2 therapy based on a
positive FISH test. For the purpose of this study the term ratio al-
ways applies to the HER2/CEP17 ratio, as deﬁned in the ASCO/CAP
guidelines [2].
Analysis of HER2 status using microarray analysis (TargetPrint)
Microarray analysis was performed at the Agendia Laboratory in
the Netherlands as previously described, using a pathology-
supported genetic testing strategy implemented in 2009 [11].
This approach largely excluded HER2-positive cases from our study
population based on the MPA developed in South Africa as a cost-
saving strategy, as risk stratiﬁcation is provided over and above
assessment of ER, PR and HER2 status already routinely performed
in all breast cancer patients using less expensive IHC/FISH meth-
odology. A minimum of 30% tumour cell percentage was accepted
for microarray analysis in accordancewith FDA requirements, using
six replicatemeasurements of HER2mRNA expression consolidated
in a single score considered positive for expression when a value of
0 was achieved [13].
Comparative analysis of HER-2 status
HER2 status determined in 138 tumour samples (41 fresh bi-
opsies and 97 FFPE specimens) were compared between locally
performed IHC/FISH results and microarray readout using Target-
Print. Concordance was regarded as the agreement between
different testing methods concerning both positive and negative
results. If different tests provided results which were negative
versus equivocal or positive versus equivocal, these results were
not regarded as discordant. Equivocal is not the same as discordant,
but poses a clinical dilemma regarding treatment decisions for
breast cancer patients with HER2 equivocal status.
Reﬂex testing
In cases where discordant results were observed between the
initial routinely performed IHC/FISH tests and TargetPrint, repeat
testing was performed on the same tumour tissue block used for
TargetPrint. For further clariﬁcation in speciﬁc cases FISH was
repeated on both the block originally used for IHC/FISH as well asthe FFPE tissue block afterwards used for TargetPrint, when dis-
crepancies were reported from tests performed on different tissue
blocks. Silver enhanced in-situ hybridization (SISH) was performed
in one sample with equivocal HER2 status reported following IHC
and FISH, to allow for quantitative scoring of the gene copy number.
The initial FISH report of this patient was not available for further
evaluation in this study. Assigning HER2 status was complicated by
the fact that results reported prior to 2013 were indicated as
equivocal when the FISH ratio ranged between 1.8 and 2.2. A ratio
of 2 is currently used as the cut-off point, deﬁning <2 as HER2-
negative and >2 as HER-positive. Results are reported as provided
in the reports available for evaluation and entered in the database
at referral.
Results
Baseline characteristics
The baseline characteristics of 138 tumour specimens evaluated
in his study are presented in relation to previous MammaPrint test
results in Table 1.
Comparison of HER2 status determined by IHC and in situ
hybridisation
FISH was performed on 24 (17.4%) of the 138 samples, based
on IHC positive (3þ) or equivocal (2þ) results (Table 2). In the
small group of IHC 3 þ cases a high discordance rate of 57% (4/7)
was observed in relation to positive FISH ampliﬁcation of HER2
(ratio >2). In the IHC 2 þ group, 75% (12/16) of tumours were
negative for HER2 ampliﬁcation when assessed by FISH. Only one
tumour reported as IHC 2 þ remained FISH/SISH equivocal for
HER2 status.
Comparison of HER2 status between IHC/FISH and TargetPrint
In four tumours TargetPrint HER2 status and the original IHC/
FISH reports were discordant, with one case reported as HER2
negative by IHC. Resolution of an equivocal IHC/FISH testing report
was also provided by TargetPrint in one sample. Reﬂex FISH/SISH
testing at two different reference laboratories after sample
Table 2
Comparison of HER2 gene ampliﬁcation determined by in situ hybridisation (ISH)
and HER2 protein expression determined by immunohistochemistry in 24 tumour
specimens.
FISH results IHC results Total
Negative (%) Equivocal (%) Positive (%)
0/1þ 2þ 3þ
Positive 1(4.8%)a 3 (12.5%) 3 (12.5%) 7
Equivocal 0 (0%) 1 (4.2%) 0 (0%) 1b
Negative 0 (0%) 12 (50%) 4 (16.7%) 16
Total 1 16 7 24
a FISH performed in IHC 0 case due to microarray result which conﬁrmed the
accuracy of Targetprint.
b IHC 2 þ remained equivocal on FISH and repeated SISH.
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the same tissue block is used. As an equivocal result is not discor-
dant, the correlation between IHC/ISH and microarray HER2 re-
ceptor status could be demonstrated with 100% agreement after
reﬂex testing, as shown in Fig. 2. This ﬂow diagram comparing IHC/
FISH with TargetPrint HER2 assessment in the total number of 138
tumour specimens analysed includes the 24 samples compared in
Table 2.Fig. 2. Flow diagram showing a comparison of HER2 status determined by IHC and in situ
appropriate.Discussion
The study was conducted at the interface between the labora-
tory and oncology practice in an attempt to address concerns over
the accuracy of standard techniques used for determination of
HER2 status in breast cancer patients. In addition to the known
inconsistencies in IHC evaluation of HER2 and reported discrep-
ancies in FISH results, an additional clinical dilemma is presented
by equivocal FISH results [2] The aim was to evaluate whether
TargetPrint might provide additional beneﬁt under these circum-
stances or potentially act as an alternative to FISH testing in pa-
tients referred for microarray analysis to further improve patient
care and cost-effectiveness.
We demonstrated the added value provided by TargetPrint
performed in conjunction with the 70-gene MammaPrint micro-
array in 138 tumour specimens. Risk reclassiﬁcation of HER2 status
based on TargetPrint following IHC/FISH reﬂex testing, supports the
clinical utility of microarray-based gene proﬁling in breast cancer
patients. Microarray-based assessment of HER2 status was highly
reproducible and accurate, effectively reducing the number of false-
positive and false-negative cases. A 100% concordance rate was
obtained between IHC/FISH and TargetPrint results for HER2hybridisation, with HER2 status determined by TargetPrint following reﬂex testing as
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fresh surgical biopsies (41 samples) or FFPE specimens (97 samples)
were used. This ﬁnding proved that use of FFPE tumour specimens
provides a reliable source of RNA for microarray analysis of HER2
status, analytically validated for the ﬁrst time in South African
breast cancer patients using TargetPrint.
In spite of the fact that our series was limited by the large
number of HER2 negative tumours due to pre-selection of the study
population according to the MPA eligibility criteria applied in South
Africa since 2009 [11], TargetPrint added important information in
the ﬁve discordant/equivocal cases identiﬁed. The patient with the
IHC-based HER2 negative tumour found to be HER2-positive ac-
cording to TargetPrint, was given the option of traztuzamab treat-
ment following conﬁrmation by FISH. The three patients reported
as HER2 positive according to the initial FISH result that were found
to be negative following reﬂex FISH testing based on the HER2
negative TargetPrint results, could be spared the substantial
expense and added toxicity of traztusamab after careful evaluation
of clinical and laboratory information obtained across three assay
platforms. HER2-positive status assigned by TargetPrint in the pa-
tient with an equivocal ISH result facilitated treatment decision-
making based on a binary value, which excluded the previous un-
certainty of indeterminate ISH reporting. To our knowledge, this is
the ﬁrst study which initiated independent FISH retesting on the
same tumour specimen used for TargetPrint when a discordant
HER2 microarray result was obtained.
External quality control processes according to ASCO/CAP
guidelines are in place in the laboratories where the IHC and FISH
tests were performed. The high discordance rate observed between
IHC 3þ and FISH ampliﬁcation of HER2 observed in our study may
be related to recent changes in IHC/FISH reporting deﬁnitions [2].
It may also be a reﬂection of our highly selected study cohort as
a consequence of the MPA applied to determine eligibility for
MammaPrint/TargetPrint in South Africa [11]. This approach
resulted in only seven IHC 3 þ tumours available for comparative
analysis in this patient subgroup after excluding most HER2 posi-
tive tumours from microarray analysis based on previous FISH re-
sults. Importantly, as a result of this study, modiﬁcation of the
testing algorithm is justiﬁed to routinely include breast cancer
patients with equivocal and borderline HER2-positive tumours for
microarray gene proﬁling. This is an important consideration as
some patients do not beneﬁt from chemotherapy despite HER2
overexpression [14]. Future referral of patients with equivocal and
borderline HER2-positive tumours for MammaPrint/TargetPrint
microarray analysis may therefore be an important step towards
chemotherapy-free therapy [9,14], which requires accurate
assessment of HER2 status facilitated by microarray analysis.
Although all current HER2 testing techniques are limited in their
ability to identify patients resistant to HER2-targeted therapy [15],
retesting of IHC 0/1 þ or FISH-negative cases is projected to be a
cost-effective clinical strategy [16]. Uncertainty regarding the
optimal cut-off value for HER2 testing in breast cancer however,
remains a source of on-going debate [2,17], In the analytical vali-
dation study of HER2 status using TargetPrint in the ﬁrst 800 pa-
tients enrolled in theMINDACT (Microarray In Node-negative and 1
to 3 positive lymph node Disease may Avoid ChemoTherapy) trial
[13], tumours were considered HER2 positive when scored 3 þ by
IHC and/or ampliﬁed by FISH (ratio 2). However, Hanna et al. [18]
supports the use of mean HER2 copy number rather than HER2:-
CEP17 ratio to deﬁne HER2 positivity in cases where HER2 ampli-
ﬁcation could be masked by co-ampliﬁcation of the centromere.
Assigning HER2 status is further complicated by genetic heteroge-
neity and non-invasive cellular components co-existing in the same
tumour, which may affect up to 40% of tumours when assessed
according to the College of American Pathologists guideline.Genetically heterogeneous tumours displaying HER2-ampliﬁed
subclones have the potential to beneﬁt from anti-HER2 therapy,
but this has not yet been proven in clinical studies [18].
Some of the discrepant results reported for HER2 status in our
study was related to the use of different FFPE tissue blocks for the
initial FISH and TargetPrint tests, conﬁrming the role of tumour
heterogeneity in this context. Therefore, the FDA requirement of a
minimum amount of 30% tumour for use of MammaPrint/Target-
Print is considered an important factor in the excellent perfor-
mance of microarray-based determination of HER2 status. In a
previous comparative study involving gene proﬁling a low per-
centage of invasive tumour in the tissue block used for Oncotype Dx
was found in the majority (7/8, 88%) of discrepant cases reported
between HER2 status using FISH versus RT-PCR [19]. In view of
these ﬁndings and the results presented in this study, equivocal and
borderline-positive HER2 status has become an important consid-
eration when use of the Oncotype DX vs MammaPrint test is
considered for chemotherapy selection. Rare categories of HER2
status not adequately covered by existing guidelines [2,20] are of
particular relevance in this context and have the potential to
change clinical practice as a result of the educational experience
linked to monitoring of the quality of HER2 assessment, in real
time, across three assay platforms (Dr Elizabeth Murray, personal
communication).
HER2 is one of the key genes evaluated as part of the Oncotype
DX recurrence score and the apparent incremental improvement in
discrimination over the established prognostic factors is considered
a limiting factor of this 21-gene RT-PCR assay. A large clinical
validation study of Oncotype DX published in 2008 reported that
the recurrence score was not predictive when determined in a
subgroup of nearly 400 patients with HER2 negative tumours [21].
Similarly, performance of the current version of PREDICT, an online
risk assessment tool that incorporates HER2 status in the model, is
not considered to improve further with use of Oncotype DX to the
same extent recently demonstrated for the 70-gene MammaPrint
proﬁle [22]. MammaPrint has the advantage that risk prediction for
distant recurrence based on the 70 genes included in the test is
calculated independent of HER2 status already determined
routinely using less expensive IHC/FISH tests [9,11]. Compared to
FISH and microarrays, Oncotype DX does not appear to accurately
identify HER2-positive breast carcinomas [5,6], found to include a
subpopulation that responds poorly to trastuzumab-based
chemotherapy [23]. Concerns over sufﬁcient evidence to base
clinical decision-making concerning eligibility for trastuzumab
therapy on multi-gene testing [5e7] do not apply to the advanced
microarray technology evaluated in comparisonwith standard IHC/
FISH in this study [24,25] Recent recommendations caution against
treatment decisions based on tumour grade alone or single bio-
markers [24], given the potential of microarrays to capture the true
biological proﬁle of multiple genes regulating the functional ac-
tivity of cancer pathways used as treatment targets [25].
Conclusions
Analytical validation of MammaPrint [8] and TargetPrint (this
study) on the basis of concordance results using FFPE tumour tissue
is an important milestone in the era of personalised genomic
medicine. Implementation of the MPA based on our pathology-
supported genetic testing approach led to safe avoidance of
chemotherapy inmore than 60% of patients previously identiﬁed as
low-risk for distant metastasis, irrespective of whether FFPE or
fresh tumour biopsies were used [11]. According to the treating
oncologists, no distant recurrence of disease or breast cancer-
related deaths occurred to date in the MammaPrint low-risk
group based on 8-year follow up data, as reported at the 9th
K.A. Grant et al. / The Breast 24 (2015) 137e142142Applied Genetics Workshop registered (Ref. number 4133) as a
Short Course at Stellenbosch University.
It is clear that the transfer from use of fresh to FFPE specimens in
2012 does not affect the microarray results negatively. TargetPrint
improves quality assurance and provides a reliable ancillary
method of assessing HER2 status in breast cancer. These ﬁndings
suggest that in patients undergoing MammaPrint gene proﬁling,
TargetPrint is a reliable alternative to standard assessment of HER2
at no additional cost. Modiﬁcation of the testing algorithm to
include equivocal and borderline HER-positive cases for referral of
MammaPrint/TargetPrint is therefore justiﬁed based on the results
presented in this study. Incorporation of TargetPrint using a
pathology-supported genetic testing strategy improves clinical care
by resolving borderline cases and also provides a second opinion on
standard protein- and DNA-based HER2 testing.
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